ArticleAmerican journal of translational research2025
MiR-124-3p inhibits proliferation, migration, and epithelial-mesenchymal transformation in gastric cancer by targeting ITGB1.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Heterogeneity study on MiRNA expression in islet cells of rat pancreatic head and tail.BMC medical genomics · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the functional interaction between miR-124-3p and integrin β1 (ITGB1) in gastric cancer.
methodsA comprehensive approach integrating bioinformatic prediction with experimental validation was employed. The study used dual luciferase reporter assay, CCK-8 assay, RT-qPCR, western blotting, wound healing assay, and transwell assays to systematically investigate the role of the miR-124-3p/ITGB1 regulatory axis in gastric cancer cell models.
resultsThis study identified a novel regulatory axis involving miR-124-3p and ITGB1. Mechanistic investigations demonstrated that miR-124-3p directly targets ITGB1, as confirmed by dual-luciferase reporter assays. Aberrant expression of miR-124-3p significantly suppressed ITGB1 mRNA and protein levels, leading to impaired oncogenic properties, including reduced proliferation, migration, and invasion of gastric cancer cells. Furthermore, ITGB1 downregulation inhibited gastric cancer cell growth and invasion while suppressing epithelial-mesenchymal transformation (EMT). Notably, key EMT regulators, such as E-cadherin, were up-regulated. These findings suggest that miR-124-3p-mediated ITGB1 downregulation effectively suppresses gastric cancer progression by inhibiting cell proliferation, invasion, and metastasis.
conclusionsmiR-124-3p functions as a tumor-suppressive miRNA that inhibits gastric cancer development through targeting ITGB1. The miR-124-3p/ITGB1 axis provides novel insight and may serve as a promising biomarker for gastric cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.